Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 500124 | NSE Symbol : DRREDDY | ISIN : INE089A01031 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
21-Mar-2025	09-May-2025	Accounts	Audited Results & Dividend Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2025 ,inter alia, to consider and approve audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending March 31, 2025 and to recommend final dividend, if any, for the financial year 2024-25 Outcome of Board Meeting Audited Financial results for the quarter and year ended March 31, 2025 (As Per BSE Announcement Dated on: 09/05/2025)
23-Dec-2024	23-Jan-2025	Quarterly Results	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter and nine months ending on December 31 2024. Dr Reddys Laboratories Ltd has informed BSE that the Board of Directors of the Company, at its meeting held on January 23, 2025, has inter alia approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024. (As Per BSE Announcement Dated on: 23/01/2025)
22-Sep-2024	05-Nov-2024	Quarterly Results	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ending on September 30 2024 Board of Directors of the Company at its meeting held on November 5, 2024, has inter alia approved the following: 1. Financial results a. Unaudited Consolidated Financial Results of the Company and its subsidiaries for the quarter and halfyear ended September 30, 2024, prepared in compliance with International Financial Reporting Standards (IFRS) as issued by International Accounting Standards Board (IASB); b. Press Release on Unaudited Financial Results of the Company for the above period. c. Unaudited Consolidated Financial Results of the Company and its subsidiaries for the quarter and halfyear ended September 30, 2024, as per Indian Accounting Standards. d. Unaudited Standalone Financial Results of the Company for the quarter and half-year ended September 30, 2024, as per Indian Accounting Standards. Pursuant to Regulation 33 of the SEBI Listing Regulations, the Limited Review Reports of the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results as mentioned at serial nos. (c) & (d) are also enclosed. 2. Investment in step-down wholly owned subsidiary company Approval of the fund infusion by way of investment in equity shares of Dr. Reddy's Laboratories LLC, Russia, a step-down wholly-owned subsidiary, upto an amount of Rs.600 Crores. The fund will be used for working capital requirements. The requisite details as required under SEBI Listing Regulations, read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, will be disclosed to the stock exchange(s) after approval of the Board of the said step-down wholly-owned subsidiary. (As Per BSE Announcement Dated on 05.11.2024)
21-Jun-2024	27-Jul-2024	Quarterly Results	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ending on June 30 2024 Outcome of Board Meeting (As Per BSE Announcement dated on 27.07.2024)
22-Mar-2024	07-May-2024	Accounts	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2024 inter alia to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending on March 31 2024 and to recommend dividend If any for the financial year 2023-24. Audited Financial results for the quarter and year ended March 31, 2024 Outcome of Board Meeting - Audited Financial Results for the quarter and year ended March 31, 2024 Dividend updates Change in Key Managerial Personnel 40th Annual General Meeting (AGM) of the Company is scheduled to be held on Monday, July 29, 2024 The Register of members and the Share Transfer books of the Company shall remain closed from Wednesday, July 17, 2024 to Friday, July 19, 2024 (both days inclusive) for the purpose of the Dividend and Annual General Meeting of the Company (As Per BSE Announcement Dated on 07.05.2024)
21-Dec-2023	30-Jan-2024	Quarterly Results	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2024 inter alia to consider and approve The unaudited financial results for the Company for the quarter and nine months ending December 31 2023 Outcome of Board meeting - Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2023. Announcement under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Unaudited Financial results for the Quarter and Nine Months ended December 31, 2023 (As Per BSE Announcement Dated on 30/01/2024)
22-Sep-2023	27-Oct-2023	Quarterly Results	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2023 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter and half year ending on September 30 2023. Outcome of Board Meeting - Unaudited Financial Results for the quarter and half-year ended September 30, 2023 Unaudited Financial results for the quarter and half-year ended September 30, 2023 (As per BSE Announcement Dated on 27/10/2023)
14-Mar-2024	28-Sep-2023	Subsidiary Company	Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
21-Jun-2023	26-Jul-2023	Quarterly Results	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2023 inter alia to consider and approve Consideration and approval of the Unaudited Financial Results of the Company for the quarter ending on June 30 2023. Outcome of Board Meeting - Unaudited Financial Results for the quarter ended June 30, 2023 Announcement under Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (SEBI Listing Regulations) Unaudited Financial results for quarter ended June 30, 2023 Retirement of Mr. Sridar Iyengar (DIN:00278512), Independent Director of the Company (As Per BSE Announcement dated on 26.07.2023)
23-Mar-2023	10-May-2023	Accounts	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2023 inter alia to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending on March 31 2023 and to recommend dividend if any for the financial year 2022-23. Outcome of Board Meeting held on May 10, 2023 - Audited Financial Results and recommendation of Dividend for FY23 39th Annual General Meeting (AGM) of the members of the Company scheduled to be held on Thursday, July 27, 2023. The Register of Members and the Share Transfer Books of the Company shall remain closed from Wednesday, July 12, 2023, to Friday, July 14, 2023 (both days inclusive) for the purpose of the Dividend and Annual General Meeting of the Company. Audited Financial Results for FY23 (As per BSE Announcement Dated on 10/05/2023)
23-Mar-2023	23-Mar-2023	Others	Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
27-Dec-2022	25-Jan-2023	Quarterly Results	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2023 inter alia to consider and approve A meeting of the Board of Directors of the Company will be held on Wednesday January 25 2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ending on December 31 2022. Outcome of Board Meeting - Unaudited Financial Results for the quarter and nine months ended December 31, 2022 Unaudited Financial Results for the quarter and nine months ended December 31, 2022 (As per BSE Announcement Dated on 25/01/2023)
28-Sep-2022	28-Oct-2022	Quarterly Results	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2022 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ending on September 30 2022. Outcome of Board Meeting - Unaudited Financial Results for the quarter and half-year ended September 30, 2022 (As Per BSE Announcement Dated on 28.10.2022)
29-Jun-2022	28-Jul-2022	Quarterly Results	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2022 inter alia to consider and approve To consider and approve the Unaudited Financial Results of the Company for the quarter ending on June 30 2022. Sale of investment in wholly-owned subsidiary - Imperial Credit Private Limited Unaudited Financial Results for the quarter ended June 30, 2022 Appointment of Mr. Arun Madhavan Kumar (DIN: 09665138) as an Additional Director, categorized as Independent, on the Board of the Company. (As Per BSE Announcement dated on 28.07.2022) Newspaper publication for unaudited financial results for Q1 FY23 (As Per BSE Announcement Dated on 30/07/2022)
29-Mar-2022	19-May-2022	Final Dividend	DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2022 inter alia to consider and approve to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ending on March 31 2022 and to recommend dividend if any for the financial year 2021-22. Dr Reddys Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 19, 2022, inter alia, has recommended a final dividend of Rs. 30/- (600%) per equity share of Rs. 5/- each for the financial year 2021-22. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 38th Annual General Meeting (AGM). Outcome of Board Meeting held on May 19, 2022 Results - Audited Financial Results for the year ended March 31, 2022. The Board recommended a final dividend of Rs.30/- (600%) per equity share of Rs. 5/- each for the financial year 2021-22. (As Per BSE Announcement Dated on 19.05.2022) The Register of Members and the Share Transfer Books of the Company shall remain closed from Wednesday, July 13, 2022 to Friday, July 15, 2022 (both days inclusive) for the purpose of the AGM and Dividend. Grant of Employee Stock Options (As Per BSE Announcement Dated on 20.05.2022)

1 2

LOGIN HERE

Dr Reddys Laboratories Ltd

Board Meeting